Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical Review. - PubMed - NCBI

Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical Review. - PubMed - NCBI

Appl Health Econ Health Policy. 2017 Mar 13. doi: 10.1007/s40258-017-0318-x. [Epub ahead of print]

Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical Review.

Vernon E1, Hiedemann B2, Bowie BH3.

Author information

Abstract

BACKGROUND:

Combined oral contraceptives (COCs) increase the risk of venous thromboembolism (VTE), particularly among women with inherited clotting disorders. The World Health Organization classifies combined hormonal contraception as an "unacceptable health risk" for women with thrombogenic mutations but advises against universal thrombophilia screening before prescribing COCs given the low prevalence of thrombophilia and high screening costs.

OBJECTIVE:

Through the lens of lifetime costs and benefits, this paper systematically and critically reviews all published economic evaluations of thrombophilia screening prior to prescribing COCs.

METHODS:

We searched relevant databases for economic evaluations of thrombophilia screening before prescribing COCs. After extracting the key study characteristics and economic variables, we evaluated each article using the Quality of Health Economic Studies (QHES) and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) instruments.

RESULTS:

Seven economic evaluations of thrombophilia screening before prescribing COCs met our inclusion criteria. Only the two economic evaluations focusing exclusively on selective screening exceeded the 75-point threshold for high-quality economic studies based on the QHES instrument, whereas only one of these exceeded the 85% CHEERS threshold. Only three of the seven economic evaluations performed sensitivity analysis on key parameters. Most studies underestimated the benefits of thrombophilia screening by comparing one-time costs of genetic screening against benefits per person-year, thus implicitly assuming a 1-year duration of COC use, neglecting the long-term implications of VTE and/or neglecting the lifetime benefits of awareness of inherited thrombophilia.

CONCLUSION:

Our review highlights the lack of methodologically rigorous economic evaluations of universal thrombophilia screening before prescribing COCs.

PMID:

 

28290105

 

DOI:

 

10.1007/s40258-017-0318-x

.-.-.-.


Last Posted: Mar 23, 2017

---

• Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical Review.  
  Vernon Erin et al. Applied health economics and health policy 2017 Mar
• Inherited Thrombophilia  
  S Collins, Genome Magazine, January 2017
• The Appropriateness and Cost of Thrombophilia Panel Testing: It’s Complicated
  S Bowen et al, CDC Blog Post, December 15, 2016
• Confirmation of genetic testing results in haemostasis and thrombosis - survey of current practice in the field.  
  Jennings I et al. Haemophilia : the official journal of the World Federation of Hemophilia 2016 Apr
• Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.  
  Tersteeg Claudia et al. Seminars in thrombosis and hemostasis 2015 Nov
• A study of thrombophilia testing and counseling practices of family physicians using the script concordance method in Calgary, Canada.  
  Schneider-MacRae N et al. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2012 Jul 18(4) 403-8
• Genetics in thrombophilia. An update.  
  Reitsma P H et al. Ha¨mostaseologie 2015 (1) 47-51
• Thrombophilia and varicella zoster in children.  
  Ferrara Mara et al. Hematology 2013 Mar (2) 119-22
• Tobacco smoking strongly modifies the association of prothrombin G20210A with undetermined stroke: Consecutive survivors and population-based controls.  
  Krajcoviechova A et al. Atherosclerosis 2015 Apr 11. (2) 446-452
• Systematic review: hereditary thrombophilia associated to pediatric strokes and cerebral palsy.  
  Torres Vinicius M et al. J Pediatr (Rio J) 2015 Jan-Feb (1) 22-9
• Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study.  
  Kovac Mirjana et al. Eur. J. Intern. Med. 2015 Jan (1) 63-7
• Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).  
  Pabinger I et al. J. Thromb. Haemost. 2015 Jan (1) 17-22
• Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients.  
  Wahba Mona Ahmed et al. Blood Coagul. Fibrinolysis 2015 Jan 6.
• Prevalence of Hereditary Thrombophilia in Patients Older Than 75 Years With Venous Thromboembolism Referred for Thrombophilia Screening.  
  Siguret Virginie et al. J. Gerontol. A Biol. Sci. Med. Sci. 2015 Feb 9.
• ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing.  
• Activated protein C resistance assay and factor V Leiden.